ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
25 oct. 2023 06h50 HE
|
ZyVersa Therapeutics
Obesity exacerbates scarring of the heart through ASC-driven inflammasome activation in the heart leading to damaging inflammation.
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
18 oct. 2023 07h05 HE
|
ZyVersa Therapeutics
Inflammasome NLRP3 activation is associated with an age-related decline in kidney health, which is compounded in the presence of kidney disease.
ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues
04 oct. 2023 07h05 HE
|
ZyVersa Therapeutics
Brain inflammation from traumatic injury releases proinflammatory cytokines that activate inflammasomes in the heart leading to damaging inflammation.
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
27 sept. 2023 07h07 HE
|
ZyVersa Therapeutics
Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment.ZyVersa is advancing a dynamic pipeline of drug candidates with...
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
22 sept. 2023 06h35 HE
|
ZyVersa Therapeutics
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP.This study demonstrated that CKD-induced IL-1β...
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
10 juil. 2023 07h37 HE
|
ZyVersa Therapeutics
Mechanical stress on the heart, such as high blood pressure, initiates NLRP3-induced inflammation through heart-brain interactions, causing heart enlargement (hypertrophic heart disease) Mechanical...
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity
28 juin 2023 07h37 HE
|
ZyVersa Therapeutics
Lupus Nephritis (“LN”) is characterized by inflammation in the kidney, protein leakage into the urine (“proteinuria”), and progressive kidney damageNLRP3 inflammasomes were extensively activated in...
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis
25 mai 2023 09h07 HE
|
ZyVersa Therapeutics
Juvenile idiopathic arthritis (“JIA”), a complex autoimmune inflammatory disorder, is the most common childhood chronic rheumatic diseaseThis is the first report documenting inflammasome activation in...
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
04 mai 2023 09h07 HE
|
ZyVersa Therapeutics
Prolonged systemic inflammation contributes to poor clinical outcomes in severe alcohol-associated hepatitis (“AH”) even after cessation of alcohol useReported data demonstrate a central role of NLRP3...
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease
10 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Increased inflammasome protein expression, NLRP1, NLRP3, ASC, and caspase-1, occurs early in Alzheimer’s disease (AD), indicating a role for multiple types of inflammasomes in disease development...